arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Dare Bioscience, Inc.

DARE
$0.62 ▼ -0.01 (-1.71%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
27 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Dare Bioscience, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $9.2M
Dividend Yield —
Revenue Growth N/M
Op. Margin None
ROIC 418.6% ↗
FCF / Share $-0.46 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$187.55K
↑ +23.0% —
Net Income Profit after all expenses
$-3.00M
↑ +31.5% —
Operating Margin Operating profit as % of sales
-143.7%
↑ +49.8% —
FCF / Share Free cash flow per share
$-0.46
↑ +26.7% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -476.8% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.77x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality →
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 56 quarters